Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; PROVENT Study Group. Levin MJ, et al. Among authors: dey k. N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20. N Engl J Med. 2022. PMID: 35443106 Free PMC article. Clinical Trial.
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, Houlihan CF, Menendez-Perez I, Pollett S, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Ivanov S, Near KA, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; COVID-19 Study to Optimally Reduce Morbidity in CareHomes and Sites with Enhanced Risk (STORMCHASER) Study Group. Levin MJ, et al. Among authors: dey k. Clin Infect Dis. 2023 Apr 3;76(7):1247-1256. doi: 10.1093/cid/ciac899. Clin Infect Dis. 2023. PMID: 36411267 Free PMC article. Clinical Trial.
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Levin MJ, Ustianowski A, De Wit S, Beavon R, Thissen J, Seegobin S, Dey K, Near KA, Streicher K, Kiazand A, Esser MT. Levin MJ, et al. Among authors: dey k. Infect Dis Ther. 2024 May 4. doi: 10.1007/s40121-024-00970-x. Online ahead of print. Infect Dis Ther. 2024. PMID: 38703336
Tissue-specific enhancer-gene maps from multimodal single-cell data identify causal disease alleles.
Sakaue S, Weinand K, Isaac S, Dey KK, Jagadeesh K, Kanai M, Watts GFM, Zhu Z; Accelerating Medicines Partnership® RA/SLE Program and Network; Brenner MB, McDavid A, Donlin LT, Wei K, Price AL, Raychaudhuri S. Sakaue S, et al. Among authors: dey kk. Nat Genet. 2024 Apr;56(4):615-626. doi: 10.1038/s41588-024-01682-1. Epub 2024 Apr 9. Nat Genet. 2024. PMID: 38594305
288 results